Emerging Therapies for Relapsed/Refractory Multiple Myeloma
Cost: FreeView Offer chevron_right
Emerging Therapies for Relapsed/Refractory Multiple Myeloma consists of a single lecture, Emerging Therapies for Relapsed/Refractory Multiple Myeloma, with discussion by Ravi Vij, MD, MBA and David Dingli, MD, PhD.
After viewing Emerging Therapies for Relapsed/Refractory Multiple Myeloma, you will be better able to :
• Identify disease-related, patient-related, and cytogenetic factors that shape treatment decisions for the management of relapsed/refractory MM
• Examine safety and efficacy data of emerging strategies for patients with MM who have received prior lines of therapies including proteasome inhibitors and immunomodulatory agents
• Adopt evidence-based best practices in managing carcinoid syndrome, including strategies to address refractory or poorly controlled symptoms
• Discuss the therapeutic implications of combination regimens involving emerging agents with currently available treatment option
This program is intended for US-based hematologist-oncologists, oncologists, oncology nurses, internal medicine physicians, family medicine/primary care physicians, and other clinicians who care for patients with multiple myeloma.